Komori
Medipal Holdings (7459) · RiskDropped

Discontinuation of Sales and Product Recalls Due to Side Effects, Foreign-Matter Contamination and Other Issues

First written in FY2016. 12 of 14 entries say "Restated". Latest entry: FY2022.

14entries
7years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2016 – FY20222016: 320162017: 220172018: 420182019: 220192020: 220202021: 020212022: 12022
Same theme, other companies
Product and Sold-Product Quality Defect, Quality Assurance and Product Liability RiskA theme 577 companies write about · 600 as a headwind · 3 as a tailwind

The whole theme swung hardest in 2026: 11 of 56 companies on the "Worse" side.

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 193 companies compared. The sentences above are computed from all 193.Comparing 200 of the theme's 603 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2022DroppedAnnual report
    No standalone disclosure of the risk of discontinuation of sales and product recalls due to side effects, foreign objects, etc. can be identified in this year's Business and Other Risks section.
  2. FY2021-Q2RestatedAnnual report

    「During the cumulative second quarter of the current consolidated fiscal year, there were no newly arising business or other risks. In addition, there were no material changes to the business or other risks described in the annual securities report for the previous fiscal year.」

    The company states that there have been no material changes regarding the risk of discontinuation of sales and product recalls due to side effects, foreign objects, etc.
  3. FY2020-Q3RestatedAnnual report

    「No new business or other risks arose during the nine months ended [the current third quarter]. There have also been no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」

    The company states that there have been no material changes regarding the risk of discontinuation of sales and product recalls due to side effects, foreign objects, etc.
  4. FY2020-Q2RestatedAnnual report

    「During the cumulative second quarter of the current consolidated fiscal year, there were no newly arising business or other risks. In addition, there were no material changes to the business or other risks described in the annual securities report for the previous fiscal year.」

    The company states that there have been no material changes regarding the risk of discontinuation of sales and product recalls due to side effects, foreign objects, etc.
  5. FY2019-Q3RestatedAnnual report

    「No new business or other risks arose during the nine months ended [the current third quarter]. There have also been no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」

    The company states that there have been no material changes regarding the risk of discontinuation of sales and product recalls due to side effects, foreign objects, etc.
  6. FY2019-Q2RestatedAnnual report

    「During the cumulative second quarter of the current consolidated fiscal year, there were no newly arising business or other risks. In addition, there were no material changes to the business or other risks described in the annual securities report for the previous fiscal year.」

    The company states that there have been no material changes regarding the risk of discontinuation of sales and product recalls due to side effects, foreign objects, etc.
  7. FY2019-Q1RestatedAnnual report

    「During the first quarter of the current consolidated fiscal year, there were no newly arising business or other risks. In addition, there were no material changes to the business or other risks described in the annual securities report for the previous fiscal year.」

    The company states that there have been no material changes regarding the risk of discontinuation of sales and product recalls due to side effects, foreign objects, etc.
  8. FY2018RestatedAnnual report

    「If products sold by the Group are subject to discontinuation of sales or product recalls due to unexpected side effects, foreign objects, or other causes, this may affect operating performance.」

    The company continues to disclose the risk of discontinuation of sales and product recalls due to side effects, foreign objects, etc.
  9. FY2018-Q3RestatedAnnual report

    「No new business or other risks arose during the nine months ended [the current third quarter]. There have also been no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」

    The company states that there have been no material changes regarding the risk of discontinuation of sales and product recalls due to side effects, foreign objects, etc.
  10. FY2018-Q2RestatedAnnual report

    「During the cumulative second quarter of the current consolidated fiscal year, there were no newly arising business or other risks. In addition, there were no material changes to the business or other risks described in the annual securities report for the previous fiscal year.」

    The company states that there have been no material changes regarding the risk of discontinuation of sales and product recalls due to side effects, foreign objects, etc.
  11. FY2017-Q3RestatedAnnual report

    「No new business or other risks arose during the nine months ended [the current third quarter]. There have also been no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」

    The company states that there have been no material changes regarding the risk of discontinuation of sales and product recalls due to side effects, foreign objects, etc.
  12. FY2017-Q2RestatedAnnual report

    「During the cumulative second quarter of the current consolidated fiscal year, there were no newly arising business or other risks. In addition, there were no material changes to the business or other risks described in the annual securities report for the previous fiscal year.」

    The company states that there have been no material changes regarding the risk of discontinuation of sales and product recalls due to side effects, foreign objects, etc.
  13. FY2017-Q1RestatedAnnual report

    「During the first quarter of the current consolidated fiscal year, there were no newly arising business or other risks. In addition, there were no material changes to the business or other risks described in the annual securities report for the previous fiscal year.」

    The company states that there have been no material changes regarding the risk of discontinuation of sales and product recalls due to side effects, foreign objects, etc.
  14. FY2016First statedAnnual report

    「If products sold by the Group are subject to discontinuation of sales or product recalls due to unexpected side effects, foreign objects, or other causes, this may affect operating performance.」

    The company discloses the risk that quality issues with products it handles may lead to suspension of sales or recalls.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
Medipal Holdings's next results are scheduled for 2026-11-05. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Discontinuation of Sales and Product Recalls Due to Side Effects, Foreign-Matter Contamination and Other Issues | MEDIPAL HOLDINGS CORPORATION (7459) | Komori